The Impact of Nebivolol Versus Metoprolol on Quality of Life

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01441570
Recruitment Status : Terminated (due to slow enrollment)
First Posted : September 27, 2011
Results First Posted : April 20, 2017
Last Update Posted : April 20, 2017
Forest Laboratories
Lahey Clinic
Information provided by (Responsible Party):
Steven Gabardi, Brigham and Women's Hospital

Brief Summary:

In an open label analysis, nebivolol has been shown to have a positive impact on quality of life in the general hypertensive population. That is, patients treated with nebivolol reported less side effects compared to those treated with metoprolol. Also, more nebivolol treated patients reached normalization of blood pressure. Although there is no data, it is believed that the impact would be similar in renal transplant recipients.

The primary goal of this study is to determine if nebivolol will improve the quality of life measurements of kidney transplant recipients as compared to those treated with metoprolol succinate. This will be measured by comparing the scores of four quality of life questionnaires taken before and after 12 weeks of treatment with study drug. Other aims of this study are to determine if the use of nebivolol is cost-effective in the renal transplant recipient; determine if there is a change in urine protein excretion and renal function with the use of nebivolol; and determine the number of patients that maintain or achieve a target blood pressure of ≤ 120/80 mmHg.

Condition or disease Intervention/treatment Phase
Transplant; Failure, Kidney Hypertension Drug: Nebivolol Drug: Metoprolol succinate Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Impact of Nebivolol Versus Metoprolol on Quality of Life Measures and Cost-effectiveness in Stable Renal Transplant Recipients
Study Start Date : February 2012
Actual Primary Completion Date : July 2013
Actual Study Completion Date : July 2013

Arm Intervention/treatment
Active Comparator: Nebivolol Drug: Nebivolol
Subject will take nebivolol daily for 12 weeks.
Other Name: Bystolic

Active Comparator: Metoprolol Succinate Drug: Metoprolol succinate
Subject will take metoprolol succinate daily for 12 weeks.
Other Name: Toprol XL

Primary Outcome Measures :
  1. Quality of Life [ Time Frame: 12 weeks; Baseline scores were measured at the Initial Screening/Enrollment Visit (Visit 1 - beginning of week 1); Follow-Up scores were measured at the End of the Study (Visit 2 - End of week 12) ]

    Primary outcome measure will be the change from the Screening/Enrollment Visit to the End of the Study/Early Termination visit in scores of four quality of life questionnaires. The four quality of life questionnaires that were used included the following:

    1. Short Form (SF)-36v2 Health Survey (Score Range = 0-100; the lower the score the more disability)
    2. Sexual Dysfunction Tool for Men = International Index of Erectile Function (IIEF) Questionnaire (Score Range = 5-25; a score of 22-25 = No erectile dysfunction; 17-21 = Mild erectile dysfunction; 12-16 = Mild to moderate erectile dysfunction; 8-11 = Moderate erectile dysfunction; 5-7 = Severe erectile dysfunction)
    3. Sexual Dysfunction Tool for Women = Changes in Sexual Functioning Questionnaire (CSFQ-14-F; Score Range = 14-70; a score at or below 42 is indicative of sexual dysfunction)
    4. Multidimensional Assessment of Fatigue (MAF) Scale (Score Range = 1-50; the higher the score the more fatigue)

Secondary Outcome Measures :
  1. Blood Pressure [ Time Frame: 12 weeks ]
    Evaluate the baseline and follow-up systolic and diastolic blood pressures for all subjects in both groups.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult renal transplant recipients, men and women between 18 and 75 years of age, inclusive.
  • Patients must be > 3 months post-transplant.
  • Patients must have stable renal function (stable renal function will be defined as those patients without infection or hospitalization [for any reason] over the past 30 days, and patients with < 20% change in their serum creatinine over the past 30 days.
  • Patients receiving corticosteroids must be receiving a daily dose of < 7.5 mg of prednisone (or therapeutic equivalents based on glucocorticoid equivalency scale).
  • All eligible patients must be receiving antihypertensive medication management which must include metoprolol tartrate or metoprolol succinate.
  • Patients may be on more than one medication to control their hypertension. Use of any other FDA-approved antihypertensive agent is permitted.
  • All eligible patients will either be at goal blood pressure (<120/80 mmHg) or have Pre-hypertension (<140/90 mmHg) or Stage I hypertension (<160/100 mmHg) at the time of study inclusion.
  • Patients who are able to comprehend and satisfactorily comply with protocol requirements.
  • Patients who signed the written informed consent given prior to entering any study procedure.

Exclusion Criteria:

  • Patients with Stage II/uncontrolled hypertension (>159/99 mmHg).
  • Patients with an easily identifiable etiology for fatigue (i.e. anemia, iron-deficiency, poor sleep patterns, etc.).
  • Patients who have a medical condition that, in the Investigator's opinion, would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the course of the trial (i.e. arrhythmia).
  • Patients with any current malignancy, or any clinically significant hematological, endocrine, cardiovascular, hepatic, gastrointestinal or neurological disease (including any form of epilepsy). If there is a history of such disease but the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included.
  • Patients who are judged by the investigator to be unable or unlikely to follow the study protocol and complete all scheduled visits.
  • Patients with any contraindications to beta blocker therapy as listed in the package labeling for both metoprolol succinate and nebivolol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01441570

United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Lahey Clinic
Burlington, Massachusetts, United States, 01805
Sponsors and Collaborators
Brigham and Women's Hospital
Forest Laboratories
Lahey Clinic
Principal Investigator: Steven Gabardi, PharmD, FCCP, BCPS Transplant Surgery

Responsible Party: Steven Gabardi, Abdominal Organ Transplant Specialist, Brigham and Women's Hospital Identifier: NCT01441570     History of Changes
Other Study ID Numbers: 2011P001638
First Posted: September 27, 2011    Key Record Dates
Results First Posted: April 20, 2017
Last Update Posted: April 20, 2017
Last Verified: March 2017

Keywords provided by Steven Gabardi, Brigham and Women's Hospital:

Additional relevant MeSH terms:
Renal Insufficiency
Vascular Diseases
Cardiovascular Diseases
Kidney Diseases
Urologic Diseases
Anti-Arrhythmia Agents
Antihypertensive Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Adrenergic beta-1 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists